MedTrace Logo

A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants

NCT06999083 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-05-31

No results posted yet for this study

Summary

The aim of this study is to investigate the safety and tolerability of HB0043 in healthy subjects following single-dose.

Conditions

  • Healthy

Interventions

DRUG

HB0043

HB0043 Drug Product

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Shanghai Huaota Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Millie Wang · New Zealand Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-03
Primary Completion
2025-12-01
Completion
2026-04-01

Countries

  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06999083 on ClinicalTrials.gov